Don’t miss – Page 116 – Endpoints News

SIGN UP

Aduhelm OK 'bittersweet' for ALS advocates; Contrasting Covid-19 vaccine readouts; GSK joins TIGIT battle; and more

Last year

FDA's controversial Aduhelm decision leaves ALS patients feeling spurned

Last year

Biotech founder placed on leave as $400M Alzheimer's startup idea comes under scrutiny

Last year

Sen. Manchin to Biden: Don't nominate Woodcock for FDA commissioner

Last year

Bristol Myers breaks the bank on Eisai's folate receptor ADC drug, laying out more than $3B+ for rights

Last year

Biden invests $3B into antiviral development for Covid-19

Last year

As it awaits pivotal review of lead drug, FibroGen bolsters its early pipeline with licensing deal for galectin program

Last year

Viral manufacturer Vibalogics plots out expansion at German site as US growth plans are underway

Last year

Sid Mukherjee's Vor adds clinical manufacturing facility at existing Boston-area site, beefing up for a commercial push

Last year

Blueprint Medicines nabs 4th approval in bid toward profitability

Last year

CureVac blames variants as a closely-watched Covid vaccine goes down in flames, failing pivotal study with woeful data

Last year

Days after controversy greeted Biogen's blockbuster Alzheimer's OK, the big biotech concedes a setback on the tau front

Last year

Chinese oncology specialist Zai Lab brokers a deal with MacroGenics for up to 4 bispecifics with a modest down payment

Last year

Amid sluggish sales and dueling lawsuits, Novartis bows out of Amgen partnership, slashes staff

Last year

New Alzheimer's drug approval fallout: Public Citizen seeks removal of FDA's Woodcock, Cavazzoni and Dunn

Last year

Michel Sadelain puts his name and new cell engineering tech behind 'agnostic' CAR-T startup chasing epigenetic antigens

Last year

Mississippi sues Eli Lilly, Sanofi and Novo over insulin prices as interchangeable biosimilars may arrive soon

Last year

Exscientia spends SoftBank's cash in bid to edge out AI rivals

Last year

Sage's second chance at depression hits the PhIII primary, but questions remain over durability, side effects

Last year

Ex-FDA commish Stephen Hahn joins Flagship, a venture group that spawned Covid-19 vaccine maker Moderna

Last year

Biogen signals a big PhIII failure as the lead gene therapy in their $800M Nightstar buyout goes down in flames

Last year

‘You have to get up on the podium’: Incoming BIO chair Paul Hastings on diversity, drug pricing and working with the FDA

Last year

Looking beyond the pandemic, Moderna appoints J&J veteran Paul Burton as new CMO

Last year

Top analyst maps a rocky road for Vertex — unless they adopt a $10B M&A campaign to save the pipeline

Last year

First page Previous page 113 114 115116117 118 119 Next page Last page